Amadea Britton

2.9k total citations · 6 hit papers
23 papers, 1.5k citations indexed

About

Amadea Britton is a scholar working on Infectious Diseases, Epidemiology and Health. According to data from OpenAlex, Amadea Britton has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 12 papers in Epidemiology and 4 papers in Health. Recurrent topics in Amadea Britton's work include SARS-CoV-2 and COVID-19 Research (14 papers), Respiratory viral infections research (11 papers) and Viral gastroenteritis research and epidemiology (7 papers). Amadea Britton is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (14 papers), Respiratory viral infections research (11 papers) and Viral gastroenteritis research and epidemiology (7 papers). Amadea Britton collaborates with scholars based in United States and United Kingdom. Amadea Britton's co-authors include Katherine E. Fleming-Dutra, Zachary Smith, Jennifer R. Verani, Nong Shang, Gordana Derado, Emma K. Accorsi, Stephanie J. Schrag, Joseph D. Miller, H. Keipp Talbot and Sarah S. Long and has published in prestigious journals such as JAMA, Clinical Infectious Diseases and Annals of the New York Academy of Sciences.

In The Last Decade

Amadea Britton

23 papers receiving 1.5k citations

Hit Papers

Association Between 3 Doses of mRNA COVID-19 Vaccine and ... 2022 2026 2023 2024 2022 2022 2023 2024 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
    2022 403 citations Emma K. Accorsi, Amadea Britton et al. JAMA profile →
  2. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
    2022 223 citations Miwako Kobayashi, Jennifer L. Farrar et al. MMWR Morbidity and Mortality Weekly Report profile →
  3. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
    2023 172 citations Michael Melgar, Amadea Britton et al. MMWR Morbidity and Mortality Weekly Report profile →
  4. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024
    2024 80 citations Ruth Link‐Gelles, Allison Avrich Ciesla et al. MMWR Morbidity and Mortality Weekly Report profile →
  5. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
    2023 76 citations Ruth Link‐Gelles, Allison Avrich Ciesla et al. MMWR Morbidity and Mortality Weekly Report profile →
  6. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
    2024 67 citations Amadea Britton, Lauren E. Roper et al. MMWR Morbidity and Mortality Weekly Report profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amadea Britton United States 15 968 569 444 190 114 23 1.5k
Yi Luo United States 18 686 0.7× 770 1.4× 286 0.6× 97 0.5× 134 1.2× 72 1.5k
Sharon Gray United States 12 775 0.8× 422 0.7× 393 0.9× 223 1.2× 32 0.3× 31 1.2k
Farid Khan United States 17 1.2k 1.3× 531 0.9× 646 1.5× 557 2.9× 125 1.1× 35 1.9k
Danielle Moulia United States 16 788 0.8× 355 0.6× 424 1.0× 123 0.6× 80 0.7× 31 1.4k
Paige Marquez United States 23 1.1k 1.1× 298 0.5× 630 1.4× 95 0.5× 37 0.3× 58 1.8k
Simon Cottrell United Kingdom 16 837 0.9× 693 1.2× 581 1.3× 389 2.0× 37 0.3× 43 1.6k
Ana Navascués Spain 18 438 0.5× 503 0.9× 158 0.4× 143 0.8× 71 0.6× 67 911
Srinivas Rao Valluri United States 15 1.0k 1.0× 137 0.2× 454 1.0× 256 1.3× 275 2.4× 44 1.6k
Iván Martínez‐Baz Spain 23 440 0.5× 967 1.7× 327 0.7× 254 1.3× 84 0.7× 77 1.3k
Sharon Balter United States 14 440 0.5× 832 1.5× 196 0.4× 104 0.5× 149 1.3× 30 1.3k

Countries citing papers authored by Amadea Britton

Since Specialization
Citations

This map shows the geographic impact of Amadea Britton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amadea Britton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amadea Britton more than expected).

Fields of papers citing papers by Amadea Britton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amadea Britton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amadea Britton. The network helps show where Amadea Britton may publish in the future.

Co-authorship network of co-authors of Amadea Britton

This figure shows the co-authorship network connecting the top 25 collaborators of Amadea Britton. A scholar is included among the top collaborators of Amadea Britton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amadea Britton. Amadea Britton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hutton, David W., Lisa A. Prosser, Angela M. Rose, et al.. (2024). Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. Vaccine. 42(24). 126294–126294. 9 indexed citations
2.
White, Elizabeth B., Lauren Grant, Josephine Mak, et al.. (2024). Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study. Clinical Infectious Diseases. 80(4). 893–900. 1 indexed citations
3.
Link‐Gelles, Ruth, Allison Avrich Ciesla, Josephine Mak, et al.. (2024). Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024. MMWR Morbidity and Mortality Weekly Report. 73(4). 77–83. 80 indexed citations breakdown →
4.
Hause, Anne M., Pedro L. Moro, James Baggs, et al.. (2024). Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024. MMWR Morbidity and Mortality Weekly Report. 73(21). 489–494. 22 indexed citations
5.
Fleming-Dutra, Katherine E., Allison Avrich Ciesla, Lauren E. Roper, et al.. (2023). Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023. MMWR Morbidity and Mortality Weekly Report. 72(7). 177–182. 11 indexed citations
6.
7.
Link‐Gelles, Ruth, Amadea Britton, & Katherine E. Fleming-Dutra. (2023). Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions. Vaccine. 42. 125492–125492. 6 indexed citations
8.
Link‐Gelles, Ruth, Allison Avrich Ciesla, Lauren E. Roper, et al.. (2023). Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023. MMWR Morbidity and Mortality Weekly Report. 72(5). 119–124. 76 indexed citations breakdown →
9.
Childs, Lana, et al.. (2023). Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults. Pathogens. 12(5). 732–732. 34 indexed citations
10.
Melgar, Michael, Amadea Britton, Lauren E. Roper, et al.. (2023). Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. American Journal of Transplantation. 23(10). 1631–1640. 26 indexed citations
11.
Moulia, Danielle, Megan Wallace, Lauren E. Roper, et al.. (2023). Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023. MMWR Morbidity and Mortality Weekly Report. 72(24). 657–662. 20 indexed citations
12.
Melgar, Michael, Amadea Britton, Lauren E. Roper, et al.. (2023). Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morbidity and Mortality Weekly Report. 72(29). 793–801. 172 indexed citations breakdown →
13.
Yousaf, Anna R, Lisa Gwynn, Zuha Jeddy, et al.. (2023). 1935. COVID-19 mRNA Vaccination Reduces the Occurrence of Post-COVID Conditions in U.S. Children Aged 5-17 Years Following Omicron SARS-CoV-2 Infection, July 2021-September 2022. Open Forum Infectious Diseases. 10(Supplement_2). 7 indexed citations
14.
Kobayashi, Miwako, Jennifer L. Farrar, Ryan Gierke, et al.. (2022). Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morbidity and Mortality Weekly Report. 71(4). 109–117. 223 indexed citations breakdown →
15.
Britton, Amadea, Katherine E. Fleming-Dutra, Nong Shang, et al.. (2022). Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. JAMA. 327(11). 1032–1032. 59 indexed citations
16.
Accorsi, Emma K., Amadea Britton, Katherine E. Fleming-Dutra, et al.. (2022). Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 327(7). 639–639. 403 indexed citations breakdown →
17.
Link‐Gelles, Ruth, Allison Avrich Ciesla, Katherine E. Fleming-Dutra, et al.. (2022). Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022. MMWR Morbidity and Mortality Weekly Report. 71(48). 1526–1530. 88 indexed citations
18.
Britton, Amadea, Kara M. Jacobs Slifka, Chris Edens, et al.. (2021). Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021. MMWR Morbidity and Mortality Weekly Report. 70(11). 396–401. 104 indexed citations
19.
Peak, Corey M., Amadea Britton, Tran Dang Nguyen, et al.. (2015). Measuring the Association Between Artemisinin-Based Case Management and Malaria Incidence in Southern Vietnam, 1991–2010. American Journal of Tropical Medicine and Hygiene. 92(4). 811–817. 9 indexed citations
20.
Turner‐Warwick, M, P L Haslam, W A McAllister, Amadea Britton, & R. Lawrence. (1986). Do Measurements of Bronchoalveolar Lymphocytes and Neutrophils, Serum Angiotensin‐converting Enzyme, and Gallium Uptake Help the Clinician to Treat Patients with Sarcoidosis?. Annals of the New York Academy of Sciences. 465(1). 387–394. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yi Luo Breakdown of academic impact, for papers by Sharon Gray Breakdown of academic impact, for papers by Farid Khan Breakdown of academic impact, for papers by Danielle Moulia Breakdown of academic impact, for papers by Paige Marquez Breakdown of academic impact, for papers by Simon Cottrell Breakdown of academic impact, for papers by Ana Navascués Breakdown of academic impact, for papers by Srinivas Rao Valluri Breakdown of academic impact, for papers by Iván Martínez‐Baz Breakdown of academic impact, for papers by Sharon Balter
Rankless by CCL
2026